Tarsus Pharmaceuticals COO Neervannan Seshadri sold 4,564 shares at $85 per share. He owned 78,532 shares afterward, and the sale represented about 5.5% of his prior holding. The ownership figures show investors both the transaction’s size and the executive’s reported remaining position.
Key Highlights
- Neervannan Seshadri’s transaction was dated September 4, 2026, and carried code S.
- Seshadri was identified as Tarsus Pharmaceuticals’ chief operating officer.
- The sale represented about 5.5% of Seshadri’s prior shareholding.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares were sold by Chief Operating Officer Neervannan Seshadri at $85 per share, with 4,564 shares changing hands.
September 4 Sale Was Reported Under Code S
The sale was dated September 4, 2026. Its transaction code was S. The record links the transaction to Seshadri’s holdings in Tarsus Pharmaceuticals, Inc. The price was stated on a per-share basis. The transaction involved 4,564 shares of Tarsus Pharmaceuticals. Seshadri’s executive title is identified in the transaction details. The reported sale size was 4,564 shares, while the stated consideration was $85 for each share sold.
Executive Holding After Transaction
Seshadri owned 78,532 shares following the transaction. The shares sold represented about 5.5% of his prior shareholding in Tarsus Pharmaceuticals. The sale represented about 5.5% of Seshadri’s prior shareholding, and 78,532 shares remained reported after the transaction. Transaction code S denotes an open-market or private sale.
FAQs
Q: What did Tarsus Pharmaceuticals COO Neervannan Seshadri sell?
A: Neervannan Seshadri sold 4,564 Tarsus Pharmaceuticals shares at $85 per share on September 4, 2026. The transaction used code S.
Q: What was Neervannan Seshadri’s Tarsus Pharmaceuticals holding after the sale?
A: Seshadri owned 78,532 Tarsus Pharmaceuticals shares following the reported transaction. The 4,564 shares sold represented about 5.5% of his prior shareholding, according to the filing.
Q: What does transaction code S mean for TARS stock?
A: The filing lists transaction code S for the sale. It also reports that Tarsus Pharmaceuticals COO Neervannan Seshadri sold 4,564 shares at $85 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.